CS MEDICA’s Nasal Protect Gel is a new and innovative treatment option that has demonstrated effectiveness in treating hay fever and allergic rhinitis, according to the results of a recent single-arm clinical trial.

Copenhagen, Denmark – CS MEDICA, a medical device company specializing in innovative nasal products, today announced the results of a single-arm clinical trial evaluating the efficacy of Nasal Protect Gel in treating hay fever/allergic rhinitis. The study enrolled 60 subjects with a history of hay fever/allergic rhinitis during the high season of pollen for a period of two weeks. The results were overwhelmingly positive, with none of the subjects reporting any allergy reaction during the study.

The trial’s primary objective was to evaluate the efficacy of Nasal Protect Gel in reducing hay fever/allergic rhinitis symptoms. The results demonstrated that 100% of the subjects reported no pollen allergy, 90% reported reduced nasal obstruction and 92% reported reduced sneezing episodes and 75% of the subjects reported a decrease in their TNSS score (Total nasal symptoms score), a widely used questionnaire that evaluates the severity of main symptoms of allergic rhinitis in different countries.

% Change – Number of Subjectts with Improvement​

Importantly, none of the subjects reported any adverse events or side effects during the study, and CS MEDICA has not received any adverse events from the market. This suggests that Nasal Protect Gel is safe for use and could provide a much-needed solution for individuals suffering from hay fever/allergic rhinitis.

Hay fever/allergic rhinitis commonly affects approximately 30% of the global population[1]. Global allergic rhinitis treatment market is estimated to be valued at US$ 14.916,9 million in 2022 and is expected to exhibit a CAGR of 4,1% during the period 2022-2030[2]. With such a high prevalence and market size, the market potential for Nasal Protect Gel is significant, and CS MEDICA has already seen increased demand for the product.

“We are thrilled with the positive results of this clinical trial, which further validates the efficacy and safety of Nasal Protect Gel in treating hay fever/allergic rhinitis,” said Lone Henriksen, CEO of CS MEDICA. “We believe that Nasal Protect Gel has tremendous potential to improve the quality of life for millions of individuals suffering from chronic rhinitis, and we are excited about the future of this product in the market.”

Nasal Protect Gel is already available on the market and has been well-received by consumers. Nasal Protect Gel is currently launched in the following countries Denmark, Sweden, Germany, United Kingdom, Spain, Serbia, Croatia, and The Netherlands, with orders pending in Romania, Israel, Palestine, and Kuwait. With the positive results from this study, CS MEDICA is optimistic about the future of Nasal Protect Gel as a safe and effective treatment option for hay fever/allergic rhinitis.

For more information on Nasal Protect Gel and CS MEDICA, please visit the company’s website at cs-medica.com.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments for autoimmune and stress-related disorders under the trademark CANNASEN® or own label options.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). more information, visit cs-medica.com, and LinkedIn.

Tags: